September 12, 2019 Contact: Sarah Seagraves, Senior VP for Marketing (405) 813-2403 sseagraves@i2E.org Oklahoma-based Kirrhos Pharmaceuticals is developing a novel, first-in-class treatment for a severe form of non-alcoholic fatty liver disease known as NASH OKLAHOMA CITY — i2E, Inc., recently led an $850,000 seed investment in Oklahoma City-based Kirrhos Pharmaceuticals, which is developing a therapeuticRead more
News
